SAN RAFAEL, Calif.,
June 28, 2018 /PRNewswire/
-- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced
that it has awarded the first five recipients of the RARE Scholars
program, an annual scholarship for students living with rare
disease. The RARE Scholars program provides up to $20,000 to students living with
mucopolysaccharidoses, phenylketonuria or Batten disease.
"We are thrilled to offer this scholarship program for the first
time to students with rare genetic diseases, who have not only
excelled academically, but also have overcome enormous challenges,"
said Jean-Jacques Bienaimé, chairman and chief executive officer of
BioMarin. "We are inspired to offer scholarships to students who
have excelled in spite of a disease diagnosed in childhood. It is
an honor to be a part of their journeys into adulthood."
The recipients of the 2018 RARE Scholars program are:
- Laken Cleveland – Northwest-Shoals Community College
- Brady Connolly – University of California: Santa Barbara
- Olivia Cummings – Indiana University: School of Medicine
- Kaylee Glasscock – Collin County Community College District
- Caitlin Kerr – Vermont Law School
"It's amazing to see members of our community receiving these
scholarships and attending college, especially because for a
condition like PKU, their disease can impair their ability to
learn," said Christine Brown, MS,
executive director of the National PKU Alliance. "Higher education
is so important, and we are thankful to BioMarin for offering this
scholarship to further help people living with a rare disease."
BioMarin announced its RARE Scholars program on Rare Disease
Day, February 28, 2018 and began
accepting applications the next day.
About BioMarin
BioMarin is a global biotechnology
company that develops and commercializes innovative therapies for
patients with serious and life-threatening rare and ultra-rare
genetic diseases. The company's portfolio consists of seven
commercialized products and multiple clinical and pre-clinical
product candidates. For additional information, please
visit www.BMRN.com. Information on BioMarin's website is
not incorporated by reference into this press release.
About RARE Scholars
RARE Scholars aims to empower
patients with continued education by recognizing students living
with rare diseases who have demonstrated leadership and
participation in school and community activities. The RARE Scholars
program distributes up to $20,000
each year, awarding $5,000 for
undergraduate four-year or graduate studies or $2,500 for two-year or vocational-technical
studies. Applicants must be accepted to or a current student in a
postsecondary or graduate level program and diagnosed with
mucopolysaccharidoses (MPS), phenylketonuria (PKU) or Batten
disease. In March 2019,
qualified students may submit an application here for the 2019/2010
school year.
Contacts:
|
|
Investors
|
Media
|
Traci
McCarty
|
Debra
Charlesworth
|
BioMarin
Pharmaceutical Inc.
|
BioMarin
Pharmaceutical Inc.
|
(415)
455-7558
|
(415)
455-7451
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/biomarin-announces-first-recipients-of-rare-scholars-scholarship-program-300673801.html
SOURCE BioMarin Pharmaceutical Inc.